TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Phase II Two-Arm, Randomized Clinical Trial of Concomitant Immunotherapy (With Interferon-Alpha and Retinoic Acid) and Radiation Therapy for the Treatment of Advanced Cervical Cancer in India
Brief Summary: The study objective:

* To evaluate the response and survival rates after treating stage III cervical cancer with retinoic acid and interferon-α combined with radiotherapy in the study group.
* To evaluate the response and survival rates after treating stage III cervical cancer patients with concomitant cisplatin and radiotherapy in the control group.
* To evaluate the safety and tolerability of the combination of retinoic acid, interferon-α and radiation therapy compared with concomitant chemo-radiation therapy.
* To determine if there is an immune response to Human Papillomavirus (HPV) by estimating serum IgG1 and IgG2 antibodies against E7 proteins of HPV types 16 and 18 before and after treatment.

The study hypothesis:

* The response rates and survival rates of retinoic acid and interferon-α combination with radiation will be better than chemo-radiation to treat stage III cervical cancer.
* Treatment with the retinoic acid, interferon-α and radiation combination therapy will be less toxic and better tolerated than chemo-radiation therapy.


Options:
A: Arm Label: Arm I: Sulfasalazine; Type: EXPERIMENTAL; Interventions: Drug: sulfasalazine | Arm Label: Arm II: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: sulfasalazine; Assigned to Arm(s): Arm I: Sulfasalazine | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II: Placebo
B: Arm Label: protons; Type: EXPERIMENTAL; Interventions: Procedure: radiation | Arm Label: carbon ions; Type: EXPERIMENTAL; Interventions: Procedure: radiation | Intervention Type: PROCEDURE; Name: radiation; Assigned to Arm(s): carbon ions, protons
C: Arm Label: Group A: Verum Acupuncture; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy, Device: Needle Acupuncture | Arm Label: Group B: Sham Acupuncture; Type: SHAM_COMPARATOR; Interventions: Radiation: Radiotherapy, Device: Needle Acupuncture | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Group A: Verum Acupuncture, Group B: Sham Acupuncture | Intervention Type: DEVICE; Name: Needle Acupuncture; Assigned to Arm(s): Group A: Verum Acupuncture, Group B: Sham Acupuncture
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: Interferon, Retinoic Acid and radiation | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin and radiation | Intervention Type: DRUG; Name: Interferon, Retinoic Acid and radiation; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Cisplatin and radiation; Assigned to Arm(s): Group B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Mild to Moderately Severe Bronchiolitis - A Double Blind Randomized Controlled Trial.
Brief Summary: To assess the efficacy of nebulized 3% hypertonic saline in improving clinical severity scores among children aged 6 weeks to 24 months with bronchiolitis.


Options:
A: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% Normal Saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% Normal Saline; Assigned to Arm(s): Nebulized 0.9% Normal Saline
B: Arm Label: Nebulized Hypertonic Saline; Type: EXPERIMENTAL; Interventions: Drug: 3% sodium chloride | Arm Label: Nebulized Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% sodium chloride | Intervention Type: DRUG; Name: 3% sodium chloride; Assigned to Arm(s): Nebulized Hypertonic Saline | Intervention Type: DRUG; Name: 0.9% sodium chloride; Assigned to Arm(s): Nebulized Normal Saline
C: Arm Label: Standard Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: L-Epinephrine and Normal Saline (0.9%) | Arm Label: Study Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-Epinephrine and Hypertonic Saline (3%) | Intervention Type: DRUG; Name: L-Epinephrine and Normal Saline (0.9%); Assigned to Arm(s): Standard Treatment | Intervention Type: DRUG; Name: L-Epinephrine and Hypertonic Saline (3%); Assigned to Arm(s): Study Treatment
D: Arm Label: hypertonic saline and usual care; Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Arm Label: usual care (oxygen therapy); Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Intervention Type: DEVICE; Name: 3% hypertonic saline; Assigned to Arm(s): hypertonic saline and usual care, usual care (oxygen therapy)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Mild to Moderately Severe Bronchiolitis - A Double Blind Randomized Controlled Trial.
Brief Summary: To assess the efficacy of nebulized 3% hypertonic saline in improving clinical severity scores among children aged 6 weeks to 24 months with bronchiolitis.


Options:
A: Arm Label: hypertonic saline and usual care; Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Arm Label: usual care (oxygen therapy); Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Intervention Type: DEVICE; Name: 3% hypertonic saline; Assigned to Arm(s): hypertonic saline and usual care, usual care (oxygen therapy)
B: Arm Label: Standard Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: L-Epinephrine and Normal Saline (0.9%) | Arm Label: Study Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-Epinephrine and Hypertonic Saline (3%) | Intervention Type: DRUG; Name: L-Epinephrine and Normal Saline (0.9%); Assigned to Arm(s): Standard Treatment | Intervention Type: DRUG; Name: L-Epinephrine and Hypertonic Saline (3%); Assigned to Arm(s): Study Treatment
C: Arm Label: Normal saline and epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Normal saline and epinephrine | Arm Label: Hypertonic saline and epinephrine; Type: EXPERIMENTAL; Interventions: Drug: Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Hypertonic saline and epinephrine; Assigned to Arm(s): Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Normal saline and epinephrine; Assigned to Arm(s): Normal saline and epinephrine
D: Arm Label: Nebulized Hypertonic Saline; Type: EXPERIMENTAL; Interventions: Drug: 3% sodium chloride | Arm Label: Nebulized Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% sodium chloride | Intervention Type: DRUG; Name: 3% sodium chloride; Assigned to Arm(s): Nebulized Hypertonic Saline | Intervention Type: DRUG; Name: 0.9% sodium chloride; Assigned to Arm(s): Nebulized Normal Saline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK 580299) in Healthy Adult Chinese Female Subjects
Brief Summary: This study is designed to evaluate the immunogenicity and safety of GSK Biologicals' human papillomavirus (HPV) vaccine in adult female subjects aged 26-45 years. One group of subjects will receive the HPV vaccine and the other group will receive an active control (GSK Biologicals' hepatitis B vaccine). Immunogenicity data of the HPV group will be compared with those from the HPV group included in the NCT00779766 study (aged 18-25 years).


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK580299 (CervarixTM) | Arm Label: Engerix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-BTM | Intervention Type: BIOLOGICAL; Name: GSK580299 (CervarixTM); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-BTM; Assigned to Arm(s): Engerix Group
B: Arm Label: Cervarix; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18 VLP/AS04 Vaccine (Cervarix TM) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: HPV-16/18 VLP/AS04 Vaccine (Cervarix TM); Assigned to Arm(s): Cervarix
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: hepatitis A inactivated virus vaccine | Intervention Type: BIOLOGICAL; Name: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: hepatitis A inactivated virus vaccine; Assigned to Arm(s): Havrix Group
D: Arm Label: Low-dose V503; Type: EXPERIMENTAL; Interventions: Biological: Experimental: V503 | Arm Label: Mid-dose V503; Type: EXPERIMENTAL; Interventions: Biological: Experimental: V503 | Arm Label: High-dose V503; Type: EXPERIMENTAL; Interventions: Biological: Experimental: V503 | Arm Label: Gardasil; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: GARDASIL, Biological: Experimental: V503 | Intervention Type: BIOLOGICAL; Name: Comparator: GARDASIL; Assigned to Arm(s): Gardasil | Intervention Type: BIOLOGICAL; Name: Experimental: V503; Assigned to Arm(s): Gardasil, High-dose V503, Low-dose V503, Mid-dose V503

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center, Double-blind, Randomized, Placebo-controlled Study of Selective 11 Beta-HSD1 Inhibition With RO5093151 for 12 Weeks to Investigate Efficacy, Safety and Pharmacokinetics of RO5093151 in Non-alcoholic Fatty Liver Disease and Its Metabolic Consequences.
Brief Summary: This multi-center, double-blind, randomized, placebo-controlled study will evaluate the change in liver fat content, pharmacokinetics and safety of RO5093151 in patients with non-alcoholic fatty liver disease. Patients will be randomized to receive either daily oral doses of RO5093151 or matching placebo. The anticipated time on study treatment is 12 weeks.


Options:
A: Arm Label: Resveratrol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Resveratrol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Resveratrol; Assigned to Arm(s): Resveratrol | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin E | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: RO5093151 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: RO5093151; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Leisure Time Physical Activity Intervention on the Overweight and the Obesity in Schoolchildren. The Cuenca's Study
Brief Summary: The purpose of this study is to evaluate the effectiveness of a recreational physical activity intervention (RPAI) for reducing the prevalence of overweight/obesity and other cardiovascular risk factors


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: CHAM JAM | Arm Label: Wait-Listed Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CHAM JAM; Assigned to Arm(s): Intervention
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cycling to school; Type: EXPERIMENTAL; Interventions: Behavioral: Cycling to school | Intervention Type: BEHAVIORAL; Name: Cycling to school; Assigned to Arm(s): Cycling to school
C: Arm Label: Movi2 Program; Type: EXPERIMENTAL; Interventions: Behavioral: Movi2 Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Movi2 Program; Assigned to Arm(s): Movi2 Program
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: School children and adolescents as health experts | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: School children and adolescents as health experts; Assigned to Arm(s): A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Leisure Time Physical Activity Intervention on the Overweight and the Obesity in Schoolchildren. The Cuenca's Study
Brief Summary: The purpose of this study is to evaluate the effectiveness of a recreational physical activity intervention (RPAI) for reducing the prevalence of overweight/obesity and other cardiovascular risk factors


Options:
A: Arm Label: parent intervention plus gym lessons; Type: EXPERIMENTAL; Interventions: Behavioral: parent-focused intervention, Behavioral: twice weekly gym lessons | Arm Label: gym lessons only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: twice weekly gym lessons | Intervention Type: BEHAVIORAL; Name: parent-focused intervention; Assigned to Arm(s): parent intervention plus gym lessons | Intervention Type: BEHAVIORAL; Name: twice weekly gym lessons; Assigned to Arm(s): gym lessons only, parent intervention plus gym lessons
B: Arm Label: Active video game play; Type: EXPERIMENTAL; Interventions: Behavioral: Active video game play | Intervention Type: BEHAVIORAL; Name: Active video game play; Assigned to Arm(s): Active video game play
C: Arm Label: Eating and physical activity counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Eating and physical activity counseling | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Eating and physical activity counseling; Assigned to Arm(s): Eating and physical activity counseling
D: Arm Label: Movi2 Program; Type: EXPERIMENTAL; Interventions: Behavioral: Movi2 Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Movi2 Program; Assigned to Arm(s): Movi2 Program

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 mcg and 5 mcg Once Daily) Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Adolescents (12 to 17 Years Old) With Severe Persistent Asthma
Brief Summary: The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) over 12 weeks, compared to placebo, as add-on controller therapy on top of usual care in adolescents (12 to 17 years old) with severe persistent asthma.

The primary objective of the trial is to demonstrate superiority of tiotropium (5 mcg and possibly 2.5 mcg once daily in the evening) over placebo with regard to the primary pulmonary function endpoint after 12 weeks of treatment.

Secondary objectives are to evaluate efficacy of tiotropium with regard to other endpoints, and to evaluate the safety of tiotropium, compared to placebo, as add-on controller therapy on top of usual care in this patient population.


Options:
A: Intervention Type: DRUG; Name: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate); Assigned to Arm(s): N/A
B: Arm Label: CHF 5993 100/6/12.5 µg; Type: EXPERIMENTAL; Interventions: Drug: CHF 5993 100/6/12.5 µg | Arm Label: CHF 1535 100/6 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: CHF 1535 100/6 µg | Intervention Type: DRUG; Name: CHF 5993 100/6/12.5 µg; Assigned to Arm(s): CHF 5993 100/6/12.5 µg | Intervention Type: DRUG; Name: CHF 1535 100/6 µg; Assigned to Arm(s): CHF 1535 100/6 µg
C: Arm Label: Arm 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm 1
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: tiotropium low dose | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: tiotropium high dose | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium high dose; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C | Intervention Type: DRUG; Name: tiotropium low dose; Assigned to Arm(s): A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Alliance for Quality of Life in Long Term Care: The Effects of a Walking Program on Balance, Falls and Well Being in Individuals Residing in Long-term Care
Brief Summary: The purpose of this study is to assess the effectiveness of a regular walking program (which inevitably involves human interaction) compared to a usual care condition and to a human interaction condition (without the extra walking program) in individuals residing in Long-Term Care (LTC). Outcomes of interest include: balance, strength, mobility, endurance, walking distance; rate and severity of falls; activities of daily living; mood and behaviour.

It is hypothesized that participants taking part in the walking program will demonstrate maximal benefits compared to the no treatment control group (usual care) and the participants who will only receive social interaction. It is expected that benefits of the walking program will include decreased fall rates, and improved balance, endurance, strength, mood, behaviour, activities of daily living and quality of life indices. Given research findings that the addition of pleasant activities improves resident mood (Teri et al, 1997; 2003), it is expected that participants in the social interaction only group will demonstrate improvements in mood and other indices of quality of life.


Options:
A: Arm Label: RASP; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmaceutical care plan, mostly based on the RASP | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmaceutical care plan, mostly based on the RASP; Assigned to Arm(s): RASP
B: Arm Label: Mulitfaceted podiatry Intervention; Type: EXPERIMENTAL; Interventions: Other: Foot and ankle exercises, foot orthoses, footwear provision | Arm Label: Usual podiatry care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Foot and ankle exercises, foot orthoses, footwear provision; Assigned to Arm(s): Mulitfaceted podiatry Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual podiatry care
C: Arm Label: Exercise with Whole-body vibration platform; Type: EXPERIMENTAL; Interventions: Device: Exercise with Whole-body vibration platform | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Intervention Type: DEVICE; Name: Exercise with Whole-body vibration platform; Assigned to Arm(s): Exercise with Whole-body vibration platform | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interpersonal Interaction; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interpersonal Interaction | Arm Label: Walking Program; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Program | Intervention Type: BEHAVIORAL; Name: Interpersonal Interaction; Assigned to Arm(s): Interpersonal Interaction | Intervention Type: BEHAVIORAL; Name: Walking Program; Assigned to Arm(s): Walking Program

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Haemodynamic Assessment at Primary Caesarean Section After Administration of Carbetocin Versus Oxytocin: a Doubleblind Randomized Trail
Brief Summary: The purpose of this study is to evaluate the immediate effects of carbetocin and oxytocin on maternal hemodynamic parameters (heart rate and blood pressure) in a non-invasive setup (TaskeForce®-Monitor) during primary Caesarean section.


Options:
A: Arm Label: Oxytocin in Uniject; Type: EXPERIMENTAL; Interventions: Other: Oxytocin in Uniject | Arm Label: PPH Treatment Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Oxytocin in Uniject; Assigned to Arm(s): Oxytocin in Uniject
B: Arm Label: Oxytocin 10 units/500cc; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 40 units/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 80U/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin 10 units/500cc, Oxytocin 40 units/500cc, Oxytocin 80U/500cc
C: Arm Label: Short infusion; Type: EXPERIMENTAL; Interventions: Drug: Carbetocin Short-infusion | Arm Label: Bolus application; Type: OTHER; Interventions: Drug: Carbetocin Bolus application | Intervention Type: DRUG; Name: Carbetocin Short-infusion; Assigned to Arm(s): Short infusion | Intervention Type: DRUG; Name: Carbetocin Bolus application; Assigned to Arm(s): Bolus application
D: Arm Label: Carbetocin; Type: N/A; Interventions: N/A | Arm Label: Oxytocin; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Haemodynamic Assessment at Primary Caesarean Section After Administration of Carbetocin Versus Oxytocin: a Doubleblind Randomized Trail
Brief Summary: The purpose of this study is to evaluate the immediate effects of carbetocin and oxytocin on maternal hemodynamic parameters (heart rate and blood pressure) in a non-invasive setup (TaskeForce®-Monitor) during primary Caesarean section.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin infusion | Intervention Type: DRUG; Name: Oxytocin infusion; Assigned to Arm(s): A
B: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Carbetocin; Type: EXPERIMENTAL; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
C: Arm Label: Carbetocin; Type: N/A; Interventions: N/A | Arm Label: Oxytocin; Type: N/A; Interventions: N/A
D: Arm Label: Oxytocin 10 units/500cc; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 40 units/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 80U/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin 10 units/500cc, Oxytocin 40 units/500cc, Oxytocin 80U/500cc

Answer: C